Celgene reveals plans to acquire Juno for $9bn

Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Celgene signs $1bn deal to develop blood cancer therapy

31 January 2019 Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

More on this story

Americas

Celgene signs $1bn deal to develop blood cancer therapy

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

More on this story

Americas

Celgene signs $1bn deal to develop blood cancer therapy

Asia-Pacific

Allergan to buy Australian tissue repair company for $95m

12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.